

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Ribo Life Science Co., Ltd.

蘇州瑞博生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6938)

VOLUNTARY ANNOUNCEMENT

KEY MILESTONE ACHIEVEMENT OF RESEARCH COLLABORATION WITH BOEHRINGER INGELHEIM

This announcement is made by Suzhou Ribo Life Science Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders of the Company (the “**Shareholders**”) and potential investors with an update on the Group’s latest research and development progress.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the third key milestone has been achieved in the research collaboration with Boehringer Ingelheim (“**BI**”) to discover novel therapies for liver disease, including metabolic dysfunction-associated steatohepatitis (MASH).

MASH is a serious and progressive form of fatty liver disease that can lead to fibrosis, cirrhosis, liver failure and liver cancer, affecting over 200 million people globally. Despite its growing burden, there remains a need for effective medicines that can help prevent disease progression and support liver health. Through the collaboration, the Company and BI aim to expand the pipeline of potential future treatment options for patients with MASH. The achievement further solidifies the Company’s position as a strategic partner for global pharma, highlighting its siRNA platform’s commercial potential.

As at the date of this announcement, the collaboration remains at a pre-clinical stage. There is no assurance that the collaboration will ultimately lead to the successful development or commercialization of any product. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Suzhou Ribo Life Science Co., Ltd.
LIANG Zicai
Chairman

Hong Kong, May 6, 2026

As of the date of this announcement, the executive Directors are Dr. LIANG Zicai, Dr. GAN Liming and Dr. ZHANG Hongyan, the non-executive Directors are Dr. QI Fei, Mr. LI Dongfang and Mr. LI Yuhui, and the independent non-executive Directors are Dr. YU Xuefeng, Mr. MA Chaosong and Mr. WANG Ruiping.